LGD-2226 | CAS#328947-93-9 | androgen receptor modulator

MedKoo Cat#: 522569 | Name: LGD-2226

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LGD-2226 is an selective androgen receptor modulator, which is being developed for treatment of muscle wasting and osteoporosis. LGD-2226 is an orally active, potent and selective agonist for androgen receptors which was shown to have anabolic effects in both muscle and bone tissue, but with considerably less effects on prostate weight and lutenizing hormone levels than testosterone.

Chemical Structure

LGD-2226

CAS#328947-93-9

Theoretical Analysis

MedKoo Cat#: 522569

Name: LGD-2226

CAS#: 328947-93-9

Chemical Formula: C14H9F9N2O

Exact Mass: 392.0571

Molecular Weight: 392.22

Elemental Analysis: C, 42.87; H, 2.31; F, 43.59; N, 7.14; O, 4.08

Price and Availability

Size	Price	Availability	Quantity
25mg	USD 1,050.00	Back order

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

LGD-2226; LGD2226; LGD 2226.

IUPAC/Chemical Name

6-(bis-(2,2,2-trifluoroethyl)amino)-4-trifluoromethyl-1H-quinolin-2-one

InChi Key

ULBPQWIGZUGPHU-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H9F9N2O/c15-12(16,17)5-25(6-13(18,19)20)7-1-2-10-8(3-7)9(14(21,22)23)4-11(26)24-10/h1-4H,5-6H2,(H,24,26)

SMILES Code

O=C1NC2=C(C=C(N(CC(F)(F)F)CC(F)(F)F)C=C2)C(C(F)(F)F)=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

LGD-2226 is an selective androgen receptor modulator.

In vitro activity:

TBD

In vivo activity:

LGD2226 exhibited anabolic activity on muscle and bone with reduced impact on prostate growth in rodent models. Biomechanical testing of bones from animals treated with LGD2226 showed strong enhancement of bone strength above sham levels. LGD2226 was also efficacious in a sex-behavior model in male rats measuring mounts, intromissions, ejaculations, and copulation efficiency. Reference: Endocrinology. 2007 Jan;148(1):363-73. https://pubmed.ncbi.nlm.nih.gov/17023534/

Preparing Stock Solutions

The following data is based on the product molecular weight 392.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, López FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73. doi: 10.1210/en.2006-0793. Epub 2006 Oct 5. PMID: 17023534. 2. Rosen J, Negro-Vilar A. Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. J Musculoskelet Neuronal Interact. 2002 Mar;2(3):222-4. PMID: 15758439.

In vitro protocol:

TBD

In vivo protocol:

1: Hong MH, Sun H, Jin CH, Chapman M, Hu J, Chang W, Burnett K, Rosen J, Negro-Vilar A, Miner JN. Cell-specific activation of the human skeletal alpha-actin by androgens. Endocrinology. 2008 Mar;149(3):1103-12. Epub 2007 Dec 6. PubMed PMID: 18063690. 2: Thevis M, Kohler M, Maurer J, Schlörer N, Kamber M, Schänzer W. Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis. Rapid Commun Mass Spectrom. 2007;21(21):3477-86. PubMed PMID: 17985352. 3: van Oeveren A, Motamedi M, Mani NS, Marschke KB, López FJ, Schrader WT, Negro-Vilar A, Zhi L. Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. J Med Chem. 2006 Oct 19;49(21):6143-6. PubMed PMID: 17034117. 4: Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, López FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73. Epub 2006 Oct 5. PubMed PMID: 17023534.